IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset neurodegenerative disorder with a poor prognosis and a median survival of 3 years. However, a significant proportion of patients survive more than 10 years from symptom onset.
RESULTS
Among the 4256 patients included in the analysis (2589 male [60.8%] and 1667 female [39.2%]; mean [SD] age at onset, 59 [12] years), the following 2 novel loci were significantly associated with ALS survival: at 10q23 (rs139550538; P = 1.87 × 10 −9 ) and in the CAMTA1 gene at 1p36 (rs2412208, P = 3.53 × 10 −8 ). At locus 10q23, the adjusted hazard ratio for patients with the rs139550538 AA or AT genotype was 1.61 (95% CI, 1.38-1.89; P = 1.87 × 10 −9 ), corresponding to an 8-month reduction in survival compared with TT carriers. For rs2412208 CAMTA1, the adjusted hazard ratio for patients with the GG or GT genotype was 1.17 (95% CI, 1.11-1.24; P = 3.53 × 10 −8
), corresponding to a 4-month reduction in survival compared with TT carriers.
CONCLUSIONS AND RELEVANCE This GWAS robustly identified 2 loci at genome-wide levels of significance that influence survival in patients with ALS. Because ALS is a rare disease and prevention is not feasible, treatment that modifies survival is the most realistic strategy. Therefore, identification of modifier genes that might influence ALS survival could improve the understanding of the biology of the disease and suggest biological targets for pharmaceutical intervention. In addition, genetic risk scores for survival could be used as an adjunct to clinical trials to account for the genetic contribution to survival.
A myotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons in which relentlessly progressive weakness of voluntary muscles usually leads to death within 3 to 5 years of symptom onset. Amyotrophic lateral sclerosis is a heterogeneous disease with a poorly understood cause. Phenotypic variability in ALS is remarkable, consisting of heterogeneity in disease duration, age at onset, onset site, and type of motor neuron affected. 1 C9orf72, 5 and sterile alpha and TIR motif containing 1 (SARM1 [NCBI Entrez Gene 23098]). 6 Despite the poor prognosis of ALS, about 5% of patients may survive more than 10 years. 7 Long-term survivors are more likely to have primary lateral sclerosis, but all phenotypic patterns are represented. Younger age at onset correlates with longer survival, and other prognostic factors include disease progression rate at diagnosis, site of involvement at onset, certain phenotypic patterns (flail limb variants), cognitive impairment, and respiratory involvement. [8] [9] [10] [11] [12] However, yet unknown factors are also likely to influence survival. Previous studies have reported an association of survival with single-nucleotide polymorphisms (SNPs) in the kinesinassociated protein 3 (KIFAP3 [NCBI Entrez Gene 22920]) and UNC13A genes, 13, 14 although the KIFAP3 finding has not been replicated. 15, 16 Identification of gene variants influencing survival is thus crucial, particularly because these factors may provide important targets for disease-modifying therapies. To identify modifier genes that might influence ALS survival, we performed a GWAS using Cox proportional hazards regression modeling that included age at onset and onset site as covariates, followed by meta-analysis.
Methods

Samples and Data
Genotypes were obtained from published GWAS of patients with sporadic ALS from Italy, the United States, the United Kingdom, Ireland, Sweden, Belgium, and France, collected by the Italian Consortium for the Genetics of ALS (SLAGEN) and International Consortium on Amyotrophic Lateral Sclerosis Genetics (ALSGEN) (eMethods and eTable 1 in the Supplement). Participating patients fulfilled the El Escorial revised criteria for ALS 17, 18 without a reported family history of motor neuron diseases. Individuals included were of European ancestry by self-declaration. Clinical information was collected from medical notes, including the date of last consultation, and survival data from death certificates or hospital or public records. The site of onset was defined as bulbar for those in whom first weakness affected speech and swallowing and as spinal for those with limb or respiratory symptoms at onset. Symptom onset was defined as the date of first weakness or speech or swallowing disturbances. Survival duration was defined as the difference between the date of death or tracheostomy and the date of symptom onset and, for those still alive, as the difference between the censor date and the date of symptom onset. The censor date was taken as date of the last follow-up. This study was approved by the ethics boards of the participating institutions, and all patients or their representatives provided written informed consent.
Genotyping, Quality Control, and Imputation Analysis The Cox proportional hazards regression baseline model included age at onset (as a continuous variable) and sex and onset site (bulbar vs spinal) as factor variables (eTable 4 in the Supplement). We tested the proportional hazards assumption by comparing the hazard curves stratified by sex, age at onset, and onset site. All tests were 2 tailed, and significance was assessed at P < .05 and performed in SPSS software (version 22; IBM Corporation).
The Cox proportional hazards model was applied genome wide to filtered imputed data in each population with the following independent variables: SNP genotype under a logadditive model, the 4 principal components of ancestry, sex, and age at onset. To maximize power in the exploratory analysis, onset site was omitted in the final model owing to the smaller numbers of patients (3438 [80.8%]) with this information. The model was built by backward elimination using the pacoxph program in the ProbABEL 21 toolset to estimate the HR with 95% CI, model, and covariate P values for each SNP. Statistical significance was assessed at the genome-wide level (P = 5 × 10 −8 ).
Summary statistics for 7 174 392 overlapping SNPs were combined in a meta-analysis using METAL software 22 weighted by β coefficients and the inverse of the corresponding standard errors; the fixed-effects model was applied to adjust data from the 7 independent data sets. Genomic inflation was tested by quantile-quantile plots and factor lambda estimate (λ (gc) = 1.05) (eMethods and eFigure 1 in the Supplement).
The most associated variants were tested for heterogeneity of allele frequencies between studies by Cochran's Q test (eMethods and eTable 5 in the Supplement). The SNPs that achieved genome-wide significance in the combined metaanalysis were tested by Kaplan-Meier analysis and a log-rank test. Kaplan-Meier curves for additive and dominant models were compared by χ 2 likelihood ratio tests.
Results
The international ALS cohort analyzed in the present study in- A total of 7 174 392 SNPs had genotypes that passed quality control measures. Two loci exceeded the genome-wide significance threshold: one on chromosome 10q23 and one on chromosome 1p36 ( Figure 1A and Table 1 ) and a median survival of 30.7 months compared with 36.7 months for the TT homozygotes ( Figure 2A and Table 2) .
Kaplan-Meier analysis of SNP rs2412208 under an additive model showed that carrying a G allele (1909 patients [44.9%]) was significantly associated with a decreased survival (log-rank P = 3.5 × 10 −8 ), with median survivals of 36.0 months (GG) and 36.8 months (GT) in contrast to 40.8 months in TT carriers ( Figure 2B and Table 2 ). The HR estimates were consistent across the 7 data sets analyzed ( Figure 3) . Under a dominant model, the results were similar ( Figure 2C ) and a χ 2 likelihood ratio test comparing the 2 models was not significant (P = .12), showing that either could be valid. We tested whether observed effect sizes (β) of the most associated SNPs from the combined Cox proportional hazards regression analysis were homogeneous across cases. We found some evidence of heterogeneity across the different data sets (rs2412208; I 2 = 57.2%; P = .03) (eTable 5 in the Supplement). In the subset of 3439 patients with ALS with clinical data including onset site, Cox proportional hazards regression was modeled with this variable as an additional covariate. The topranked SNP was rs2412208 at 1p36 with the combined HR of 1.19 (95% CI, 1.27-1.12; P = 5.11 × 10 −8 ) (eFigure 2 and eTable 8 in the Supplement), confirming association of the CAMTA1 locus with ALS survival identified by the larger sample size when this covariate was not included in the model. The SNP rs139550538 in IDE gene was less significant (HR, 1.51; 95% CI, 1.27-1.78; P = 2.24 × 10 −6 ), possibly because of the lower frequency of this SNP in a reduced sample. In addition, in linear regression analysis testing bulbar vs spinal phenotypes, this variant was not significantly associated (P = .50), indicating that the onset site was unlikely to confound the 10q23 association with survival. Kaplan-Meier distribution of rs2412208 genotypes indicated that risk allele G was associated (log-rank P = 5 × 10 −6 ) with a shorter survival of 3.5 months, which corresponded to a 19% increased rate of mortality compared with the TT ho- 
Discussion
We have identified 2 loci associated with survival in patients with ALS at genome-wide significance in a large metaanalysis using Cox proportional hazards regression analysis. The discovery of gene variants within the IDE and CAMTA1 ]) were common (MAF > 0.26). B and C, Regional linkage disequilibrium (LD) plots of the 2 regions significantly associated with ALS survival. At the 1p36 locus, 4 SNPs passed the genome-wide significant threshold, followed by 87 tagged proxies suggestively associated (P < 10 −4 ). All the associated SNPs mapped within introns 3 to 4 of the CAMTA1 gene. At the 10q23 locus, the top-ranked SNP, rs139550538, intronic to the IDE gene, was in weak (r 2 < 0.4) LD with the tagged proxies that were located in the neighbor gene, KIF11.
genes as survival modifiers in ALS is important because of improved understanding of the disease process and because the genes and associated pathways might become a target for therapy development. Furthermore, if gene variants have a large effect on survival, we must account for this evidence in the design and analysis of clinical trials.
The effect size of the variants found is comparable to that of riluzole, a drug shown to improve survival in ALS, for which the HR for those not taking vs taking riluzole is 1.14. A weakness of our study is that the extent of riluzole use was not available to include in the analysis. Generally, rates of prescription are higher in countries in which access to health care is free or reimbursed than in those where private insurance is required, and if such differences correlate with allele frequency differences, a spurious association might arise. We mitigated against this association by accounting for differences in allele frequency by ancestry using principal components and by accounting for differences in riluzole prescription rates by performing a meta-analysis stratified by country. Multidisciplinary clinic attendance has also been reported to increase survival, 25 ,26 which also may vary across countries, but we have accounted for this possibility through the country-stratified meta-analysis.
The most associated polymorphism at the 10q23 locus was a low-frequency variant within the IDE gene, a zinc metallopeptidase that degrades intracellular insulin and other peptides, such as β-amyloid. Tagged proxies for this polymorphism were in weak (r 2 < 0.4) linkage disequilibrium and Increasing evidence suggests an association between ALS and cerebellar degeneration that is currently underrecognized, in the same way as the association between ALS and frontotemporal dementia remained undetected until recently. A strength of our study is, to our knowledge, the use of the largest data set for sample size (n = 4256) and genotyped SNP coverage (>7 million) analyzed to date. In addition, the use of a Cox proportional hazards regression model allowed us to include 1131 patients still alive (26.6%), meaning the study was not biased by the restriction of a linear regression method limited to patients who have died. In contrast, a potential weakness of our study is the difficulty of imputing low-frequency variants; a reference panel including disease-specific genotype data will improve imputation of rare variants. 
SLAGEN United Kingdom Summary
Hazard ratio estimates are measured under an additive genetic model across the 7 genome-wide association study (GWAS) data sets (described in detail in eTable 1 in the Supplement). The HR in each cohort was estimated in a multivariate log-additive genetic model using the pacoxph program adjusted by age at onset, sex, and population stratification, whereas the summary HR was calculated by fixed-effects meta-analysis using R library rmeta. Genotype raw data included in each study and combined in the meta-analysis were collected by the Medical Center Utrecht, Utrecht, the Netherlands (UMC-1 and -2), the Beaumont Hospital Dublin, Ireland (Ireland), Massachusetts General Hospital, Boston (MGH), the National Institutes of Health, Bethesda, Maryland (NIH-IT), the Italian Consortium for the Genetics of ALS (SLAGEN), and the UK National MND DNA and Biobank Study (UK 
